1. Home
  2. APLM vs VRME Comparison

APLM vs VRME Comparison

Compare APLM & VRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • VRME
  • Stock Information
  • Founded
  • APLM 2016
  • VRME 1999
  • Country
  • APLM United States
  • VRME United States
  • Employees
  • APLM N/A
  • VRME N/A
  • Industry
  • APLM Blank Checks
  • VRME EDP Services
  • Sector
  • APLM Finance
  • VRME Technology
  • Exchange
  • APLM Nasdaq
  • VRME Nasdaq
  • Market Cap
  • APLM 15.6M
  • VRME 6.4M
  • IPO Year
  • APLM N/A
  • VRME N/A
  • Fundamental
  • Price
  • APLM $9.75
  • VRME $0.63
  • Analyst Decision
  • APLM Strong Buy
  • VRME Buy
  • Analyst Count
  • APLM 2
  • VRME 1
  • Target Price
  • APLM $425.00
  • VRME $1.50
  • AVG Volume (30 Days)
  • APLM 107.4K
  • VRME 241.1K
  • Earning Date
  • APLM 02-15-2025
  • VRME 11-12-2024
  • Dividend Yield
  • APLM N/A
  • VRME N/A
  • EPS Growth
  • APLM N/A
  • VRME N/A
  • EPS
  • APLM N/A
  • VRME N/A
  • Revenue
  • APLM $2,101,000.00
  • VRME $25,259,000.00
  • Revenue This Year
  • APLM N/A
  • VRME N/A
  • Revenue Next Year
  • APLM N/A
  • VRME $5.00
  • P/E Ratio
  • APLM N/A
  • VRME N/A
  • Revenue Growth
  • APLM 70.54
  • VRME N/A
  • 52 Week Low
  • APLM $6.50
  • VRME $0.58
  • 52 Week High
  • APLM $105.00
  • VRME $2.45
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.39
  • VRME 36.27
  • Support Level
  • APLM $7.23
  • VRME $0.59
  • Resistance Level
  • APLM $8.88
  • VRME $0.68
  • Average True Range (ATR)
  • APLM 1.37
  • VRME 0.07
  • MACD
  • APLM 0.21
  • VRME 0.02
  • Stochastic Oscillator
  • APLM 57.91
  • VRME 29.00

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About VRME VerifyMe Inc.

VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.

Share on Social Networks: